AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer · Kalaris Therapeutics, Inc. (KLRS)

Vikas Sinha

A named executive officer of Kalaris Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,100,954

Salary $81,106Stock awards $0

FY2024: $544,400

4th of 5 named executive officers at Kalaris Therapeutics by FY2025 total.

5 named officers on file for Kalaris Therapeutics, FY2025

Vikas Sinha’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kalaris Therapeutics’s whole pay program stands against its peers

  • Kalaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KLRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A).

Free

Get Vikas Sinha’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Vikas Sinha compensation by year

Kalaris Therapeutics Summary Compensation Table · all 7 fiscal years held
In US dollars, as Kalaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$400,000$412,000$425,000$369,007$373,042$375,448$81,106
Bonus$5,000$0$0$0$0$0$0
Stock awards$1,029,746$0$2,478,420$1,386,290$1,047,375$0$0
Option awards$0$5,665,640$3,522,326$981,658$1,520,252$0$0
Non-equity incentive$192,000$238,960$191,250$162,454$0$168,952$0
Pension and deferred compensation$0$0$0$0$0$0$0
All other$2,900$3,940$6,000$4,753$0$0$1,019,848
Total$1,629,646$6,320,540$6,622,996$2,904,162$2,940,669$544,400$1,100,954

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177362, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-26-177362. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$1.6M
$6.3M
$6.6M
$2.9M
$2.9M
$544K
$1.1M
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU3,851$37,209—
RSU1,902$18,373—
RSU663$6,405—
RSU559$5,400—
RSU159$1,536—
Option7,153—$152.95
Option1,038—$94.99
Option1,619—$210.45
Option296—$969.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Kalaris Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Kalaris Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Andrew OxtobyPresident and Chief Executive Officer$2,569,115
Matthew FeinsodChief Medical Officer$1,673,771
Brett HagenChief Accounting Officer and AlloVir’s former Chief Accounting Officer$1,439,174
Vikas Sinha · this pageAlloVir’s Former Chief Executive Officer, President and Chief Financial Officer$1,100,954
Matthew GallFormer Chief Financial Officer$1,064,607

Board service

Kalaris Therapeutics board · FY2023

How this board is paid

Company policy: Kalaris Therapeutics pays directors a $40,000 cash retainer. As stated in Kalaris Therapeutics's FY2023 proxy.

The full Kalaris Therapeutics compensation record

free company brief

This page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Vikas Sinha's compensation dossier · One-time report. No refunds.